An interventional study of Endoscopic mucosal band ligation in Gastro Esophageal Reflux Disease, sponsored by St. Olavs Hospital. Enrolling by invitation at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by St. Olavs Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Gastroesophageal Reflux with a site in Norway — 3 open to participants now, 4 under way, none of them phase 3. Gastroesophageal Reflux · Norway.
Among the 15 studies in Gastroesophageal Reflux with a site in Norway, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 13th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →3 of the 15 studies in Gastroesophageal Reflux with a site in Norway are open now. Recruiting first, the newest first:
Helse Forde · Sites in Norway
Ages 18+
Implantica CE Reflux Ltd. · Sites in Norway, Germany, Italy and 1 more country
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 297 across the 12 interventional studies, 2,370 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 7 most frequent:
St. Olavs Hospital is the lead sponsor of 171 studies on the registry; 29 are open to participants now.
St. Olavs Hospital has 1 study filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastroesophageal Reflux with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04469712Aleris HospitalNon-randomized Prospective Comparison Between SASI Bipartition and RYGB | 2027-07-01 |
| NCT05678491St. Olavs HospitalEndoscopic Treatment of Gastroesophageal Reflux Disease | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Gastroesophageal Reflux with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gastroesophageal reflux disease (GERD) occurs when stomach acid repeatedly flows back into the tube connecting your mouth and stomach (esophagus). This backwash (acid reflux) can irritate the inner lining of the esophagus. This is a particular problem after surgery to reduce obesity called gastric sleeve resection.
The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation. The main questions it aims to answer are:
Participants (n=12) will be asked to undergo 24 h reflux examination and report symptoms of GERD. Suitable patients will be offered endoscopic treatment with band ligation of the inner lining of the lower esophagus and upper part of the stomach. The effects will be assessed three and six months after the procedure.
Gastroesophageal reflux disease (GERD) is very common after gastric sleeve resection and many patients are dependent on daily use of proton pump inhibitors (PPIs). The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation.
Patients (n=12) with GERD satisfying inclusion and exclusion criteria will be invited to participate and the degree of gastroesophageal reflux will be assessed before treatment, and three and six months after the procedure. The results of the trial will be used to plan a larger study.
Inclusion Criteria (all criteria must be fulfilled):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All 12 patients with GERD will undergo the same procedure. Multiple rubber bands will be used to ligate mucosa in the gastroesophageal junction and cardia in 3/4 of the circumference.
Other: Endoscopic mucosal band ligation
The mucosa in 3/4 of the circumference of the gastroesophageal junction and cardia will be treated with mucosal band ligation left in place. This will be done during upper endoscopy in sedation. It is the endoscopic procedure that is being investigated.
Change from baseline esophageal 24 hour pH/impedance at 3 months
Esophageal pH/impedance will be measured by a catheter left in place for 24 hours
Time frame: 3 months
Change from baseline esophageal 24 hour pH/impedance at 6 months
Esophageal pH/impedance will be measured by a catheter left in place for 24 hours
Time frame: 6 months
Change from baseline symptoms of gastroesophageal reflux at 3 months
GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)
Time frame: 3 months
Change from baseline symptoms of gastroesophageal reflux at 6 months
GERD Q score. Gastroesophageal reflux disease Questionnaire with minimum value 0 (no symptoms) and maximum value 18 (severe symptoms)
Time frame: 6 months
Change from baseline in use of proton pump inhibitors (PPI) at 3 months
PPI use (number of days PPI was used during the period 7-14 days before the 3 months visit)
Time frame: 3 months
Change from baseline in use of proton pump inhibitors (PPI) at 6 months
PPI use (number of days PPI was used during the period 7-14 days before the 6 months visit)
Time frame: 6 months
Adverse events during the study period of 6 months
Adverse events or complications of the treatment will be registered during the study period
Time frame: 6 months
Change from baseline in dysphagia at 3 months
Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).
Time frame: 3 months
Change from baseline in dysphagia at 6 months
Dysphagia assessed by Marks score. The minimum value is 0 (no dysphagia) and the maximum value is 6 (can not eat, which is the most severe symptom).
Time frame: 6 months
Change from baseline in Hills flap valve at 3 months
The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)
Time frame: 3 months
Change from baseline in Hills flap valve at 6 months
The Hills flap valve assessed during endoscopy. Minimum value is 1 (good function) and the maximum value is 4 (poor function)
Time frame: 6 months
Plan to share: No — The plan is to publish all relevant data from this small trial with the detail level permitted by the local approval. Further data sharing will not be planned for.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.
Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 23 months is below that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jul 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.